Note 2 - Summary of Significant Accounting Policies (Tables)

6 Months Ended

Jun. 30, 2023

Notes Tables

Schedule of Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents [Table Text Block]

	June 30,		December 31,
	2023		2022
Cash and cash equivalents	$	4,414	$	5,362
Restricted cash included in other assets		476		484
Total cash, cash equivalents, and restricted cash in the condensed consolidated statements of cash flows	$	4,890	$	5,846

Schedules of Concentration of Risk, by Product [Table Text Block]

	Three Months Ended June 30,				Six Months Ended June 30,
	2023		2022		2023		2022
Avenova Spray	$	1,758	$	2,001	$	3,695	$	3,840
DERMAdoctor		1,076		752		1,861		1,795
NeutroPhase		1,043		509		1,043		657
Other products		722		398		1,117		635
Total product revenue, net		4,599		3,660		7,716		6,927
Other revenue, net		11		2		18		8
Total sales, net	$	4,610	$	3,662	$	7,734	$	6,935

Schedules of Concentration of Risk, by Risk Factor [Table Text Block]

	June 30,			December 31,
Major distribution partner	2023			2022
Avenova Spray Pharmacy Distributor A		28	%		11	%
Avenova Spray Pharmacy Distributor B		27	%		30	%
Major U.S. Retailer A		*	%		15	%

Schedule of Error Corrections and Prior Period Adjustments [Table Text Block]

	Three Months Ended June 30, 2022										Six Months Ended June 30, 2022
	As Previously Reported			Selling Commissions		Fulfillment Fees		As Revised			As Previously Reported			Selling Commissions		Fulfillment Fees		As Revised
Sales
Product revenue, net	$	3,043		$	288	$	329	$	3,660		$	5,666		$	586	$	675	$	6,927
Product cost of goods sold
Product cost of goods sold		1,495			-		329		1,824			2,608			-		675		3,283
Operating expenses
Sales and marketing		1,752			288		-		2,040			3,439			586		-		4,025
Net loss		(2,155	)		-		-		(2,155	)		(2,266	)		-		-		(2,266	)
Net loss per share attributable to common stockholders (basic and diluted)		(1.43	)		-		-		(1.43	)		(1.54	)		-		-		(1.54	)

Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]

	Three Months Ended June 30,						Six Months Ended June 30,
Numerator	2023			2022			2023			2022
Net loss	$	2,036		$	(2,155	)	$	(3,775	)	$	(2,266	)
Less: Retained earnings reduction due to preferred stock down round feature triggered		(1,996	)		-			(1,996	)		-
Net loss attributable to common stockholders (basic and diluted)	$	(4,032	)	$	(2,155	)	$	(5,771	)	$	(2,266	)
Denominator
Weighted average shares of common stock outstanding (basic and diluted)		3,176			1,507			2,609			1,469
Net loss per share (basic and diluted)	$	(1.27	)	$	(1.43	)	$	(2.21	)	$	(1.54	)

Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]

	As of June 30,
	2023		2022
Series B Preferred Stock		7,050		830
Series C Preferred Stock		845		—
Stock options		115		127
Stock warrants		7,382		1,274
		15,392		2,231